Co-administration of midazolam and psilocybin: Differential effects on subjective quality versus memory of the psychedelic experience
OpenAlex – June 13, 2024
Source: OpenAlex
Summary
The profound psychological benefits of the serotonergic hallucinogen psilocybin may depend on remembering the experience. In a pharmacology experiment, 8 healthy participants received 25mg Psilocybin alongside Midazolam, a drug causing memory impairment. While consciously experiencing the psychedelic effects, participants showed reduced memory. Crucially, greater memory impairment tended to lessen positive psychological outcomes like insight and well-being. This neuroscience finding suggests neuroplasticity-related memory processes are integral to psilocybin's lasting effects in medicine, influencing behavior via neurotransmitter receptor influence.
Abstract
Abstract Aspects of the acute experience induced by the serotonergic psychedelic psilocybin predict symptomatic relief in multiple psychiatric disorders and improved well-being in healthy participants, but whether these therapeutic effects are immediate or are based on memories of the experience is unclear. To examine this, we co-administered psilocybin (25 mg) with the amnestic benzodiazepine midazolam in 8 healthy participants and assayed the subjective quality of, and memory for, the dosing-day experience. We identified a midazolam dose that allowed a conscious psychedelic experience to occur while partially impairing memory for the experience. Furthermore, midazolam dose and memory impairment tended to associate inversely with salience, insight, and well-being induced by psilocybin. These data suggest a role for memory in therapeutically relevant behavioral effects occasioned by psilocybin. Because midazolam blocks memory by blocking cortical neural plasticity, it may also be useful for evaluating the contribution of the pro-neuroplastic properties of psychedelics to their therapeutic activity.